文摘
双盲,安慰剂对照研究中,我们评估的有效性吸入布地奈德对新诊断肺结节病和布地奈德治疗是否可以推迟口服皮质类固醇治疗。我们评估:1)症状;2)胸片;3)在血清血管紧张素转换酶(ACE);和4)肺功能。组织学证实肺结节病患者胸部影像学阶段我II或III,肺功能异常(吸气肺活量(IVC) < 79%的预测或转移因子的肺一氧化碳(TL公司)< 77% pred)包括在内。射线阶段II或III但患者与正常肺功能包括总细胞数的20%以上,在支气管肺泡灌洗液(BALF)淋巴细胞。40 7个患者接受安慰剂或布地奈德(1.2毫克)每天一次通过Nebuhaler 6个月,紧随其后的是6个月没有治疗。基于预先确定的标准,11盲目治疗期间患者被排除在外,他们需要口服强的松:7个(28%)病人安慰剂组(n = 25)和四个(18%)病人布地奈德组(n = 22)。病人的全球临床印象(GCI)为支持布地奈德的得分表现出显著差异。 IVC showed a significant difference of 7.9% predicted between the two groups during the active treatment period. This difference persisted during follow-up, when the difference was 9.4% pred. TL,CO remained nearly unchanged over time, with no difference between the groups. Improvements in chest radiographic appearance and changes in serum ACE were similar for the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)